


Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming

Graphical Abstract



Authors

Raquel Buj, Chi-Wei Chen, Erika S. Dahl, ..., David J. DeGraff, Nathaniel W. Snyder, Katherine M. Aird

Correspondence

kaird@psu.edu

In Brief

Senescence bypass through p16 loss predisposes to transformation and tumorigenesis. Buj et al. found that the loss of p16 upregulates nucleotide metabolism through increased mTORC1-mediated translation of *RPIA* to bypass senescence in an RB-independent manner. Thus, the mTORC1-*RPIA* axis is a metabolic vulnerability for p16-null cancers.

Highlights

- p16 knockdown activates mTORC1 to increase nucleotide synthesis and bypass senescence
- mTORC1 directly increases translation of *RPIA* to increase ribose-5-phosphate
- Activation of the mTORC1 pathway downstream of p16 suppression is independent of RB
- *RPIA* suppression induces senescence only in cells and tumors with low p16



Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming

Raquel Buj,¹ Chi-Wei Chen,¹ Erika S. Dahl,¹ Kelly E. Leon,¹ Rostislav Kuskovsky,² Natella Maglakelidze,³ Maithili Navaratnarajah,¹ Gao Zhang,^{4,9} Mary T. Doan,² Helen Jiang,² Michael Zaleski,⁵ Lydia Kutzler,¹ Holly Lacko,¹ Yiling Lu,⁶ Gordon B. Mills,⁷ Raghavendra Gowda,⁸ Gavin P. Robertson,⁸ Joshua I. Warrick,⁵ Meenhard Herlyn,⁴ Yuka Imamura,⁸ Scot R. Kimball,¹ David J. DeGraff,⁵ Nathaniel W. Snyder,² and Katherine M. Aird^{1,10,*}

¹Department of Cellular & Molecular Physiology, Penn State College of Medicine, Hershey, PA 17033, USA

²A.J. Drexel Autism Institute, Drexel University, Philadelphia, PA 19104, USA

³MSTP Program, Penn State College of Medicine, Hershey, PA 17033, USA

⁴Molecular and Cellular Oncogenesis Program and Melanoma Research Institute, The Wistar Institute, Philadelphia, PA 19104, USA

⁵Department of Pathology, Penn State College of Medicine, Hershey, PA 17033, USA

⁶Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

⁷Department of Cell, Developmental & Cancer Biology, Oregon Health and Sciences University, Portland, OR 97201, USA

⁸Department of Pharmacology, Penn State College of Medicine, Hershey, PA 17033, USA

⁹Present address: Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA

¹⁰Lead Contact

*Correspondence: kaird@psu.edu

<https://doi.org/10.1016/j.celrep.2019.07.084>

SUMMARY

Reprogrammed metabolism and cell cycle dysregulation are two cancer hallmarks. p16 is a cell cycle inhibitor and tumor suppressor that is upregulated during oncogene-induced senescence (OIS). Loss of p16 allows for uninhibited cell cycle progression, bypass of OIS, and tumorigenesis. Whether p16 loss affects pro-tumorigenic metabolism is unclear. We report that suppression of p16 plays a central role in reprogramming metabolism by increasing nucleotide synthesis. This occurs by activation of mTORC1 signaling, which directly mediates increased translation of the mRNA encoding ribose-5-phosphate isomerase A (*RPIA*), a pentose phosphate pathway enzyme. p16 loss correlates with activation of the mTORC1-RPIA axis in multiple cancer types. Suppression of RPIA inhibits proliferation only in p16-low cells by inducing senescence both *in vitro* and *in vivo*. These data reveal the molecular basis whereby p16 loss modulates pro-tumorigenic metabolism through mTORC1-mediated upregulation of nucleotide synthesis and reveals a metabolic vulnerability of p16-null cancer cells.

INTRODUCTION

Metabolic reprogramming is a hallmark of cancer (Hanahan and Weinberg, 2011; Pavlova and Thompson, 2016). Transformed and tumorigenic cells require increased deoxyribonucleotide synthesis to fuel the genome replication that sustains their unregulated cell cycle and proliferation. Therefore, it is likely that the cell cycle and nucleotide metabolism are linked. The cell cy-

cle inhibitor p16 is a critical tumor suppressor that is lost as an early event in the progression from senescent benign lesions to cancer (Bennecke et al., 2010; Bennett, 2016; Caldwell et al., 2012; Kriegl et al., 2011; Michaloglou et al., 2005; Shain et al., 2015). Indeed, expression of p16 is low or null in approximately half of all human cancers (Li et al., 2011). Although the loss of p16 is known to play a role in deregulating the cell cycle, whether the loss of p16 expression affects nucleotide metabolism is unknown.

Both increased expression of p16 (Serrano et al., 1997) and decreased levels of deoxyribonucleotide triphosphates (dNTPs) (Aird et al., 2013; Mannava et al., 2013) are characteristics of cellular senescence, a stable cell cycle arrest (Aird and Zhang, 2014, 2015; Dörr et al., 2013; Hernandez-Segura et al., 2018; Wiley and Campisi, 2016). Activation of oncogenes such as BRAF^{V600E} induces senescence to suppress transformation and tumorigenesis (termed oncogene-induced senescence [OIS]) (Pérez-Mancera et al., 2014; Yaswen and Campisi, 2007). Therefore, OIS is considered an important tumor suppressor mechanism *in vivo* (Braig et al., 2005; Michaloglou et al., 2005). Increased dNTPs or loss of p16 bypasses OIS to allow for transformation and tumorigenesis (Aird et al., 2013, 2015; Damsky et al., 2015; Dankort et al., 2007; Goel et al., 2009; Haferkamp et al., 2008; Sarkisian et al., 2007). Thus, we reasoned that these two processes may be interconnected. Here, we used senescence as a model to study the link between p16 and nucleotide metabolism. We demonstrate that the loss of p16 increases nucleotide synthesis through upregulation of mTORC1 activity.

RESULTS

p16 Knockdown Enhances Nucleotide Synthesis to Bypass Senescence

To determine whether p16 loss affects nucleotide synthesis, we took advantage of our previously published model of






Figure 1. Suppression of p16 Increases Nucleotide Synthesis to Bypass Senescence

(A–E) IMR90 cells expressing shRNA targeting RRM2 (shRRM2) alone or in combination with an shRNA targeting p16 (shp16). One of 5 experiments is shown. (A) Immunoblot analysis of the indicated proteins.

(B) Senescence-associated-β-galactosidase (SA-β-Gal) activity, bromodeoxyuridine (BrdU) incorporation, and colony formation (CF). One of 5 experiments is shown. Scale bar, 10 μm.

(C) Quantification of SA-β-Gal activity in (B). n = 3/group; 1 of 5 experiments is shown. Data represent mean ± SD. *p < 0.001.

(D) Quantification of BrdU incorporation in (B). n = 3/group; 1 of 5 experiments is shown. Data represent mean ± SEM. *p < 0.001.

(E) Quantification of colony formation in (B). n = 3/group; 1 of 5 experiments is shown. Data represent mean ± SEM. *p < 0.001.

(F–J) IMR90 cells expressing BRAF^{V600E} alone or in combination with an shRNA targeting p16 (shp16).

(F) Immunoblot analysis of the indicated proteins. One of 3 experiments is shown.

(G) SA-β-Gal activity, BrdU incorporation, and colony formation (CF). One of 5 experiments is shown. Scale bar, 10 μm.

(H) Quantification of SA-β-Gal activity in (G). n = 3/group; 1 of 5 experiments is shown. Data represent mean ± SD. *p < 0.001.

(I) Quantification of BrdU incorporation in (G). n = 3/group; 1 of 5 experiments is shown. Data represent mean ± SEM. *p < 0.002.

(J) Quantification of colony formation in (G). n = 3/group; 1 of 5 experiments is shown. Data represent mean ± SEM. *p < 0.001.

(K–N) Deoxyribonucleotide analysis in the RRM2 (K) and BRAF^{V600E} (L) models and ribonucleotide analysis in the RRM (M) and BRAF^{V600E} (N) models. n > 3/group; 1 of at least 2 experiments is shown. Data represent mean ± SEM. *p < 0.05. NA, not available.

See also Figure S1 and Data S1.

dNTP-depletion-induced senescence by knocking down RRM2 (Aird et al., 2013). Knockdown of p16 in shRRM2 cells suppressed senescence markers (Figures 1A–1E and S1A). Data using a second independent hairpin targeting p16 and overexpression of p16 cDNA demonstrate that these results are p16

specific (Figures S1B–S1K). Knockdown of p16 in the pathologically relevant model of BRAF^{V600E}-induced senescence also bypassed senescence (Figures 1F–1J). Knockdown of p16 in both models significantly increased deoxyribonucleotide diphosphates (dNDPs)/dNTPs even above control levels in some




Figure 2. Suppression of p16 Activates mTORC1 to Increase Nucleotide Synthesis

(A) IMR90 cells expressing shRNA targeting RRM2 (shRRM2) alone or in combination with an shRNA targeting p16 (shp16) and treated with temsirolimus (Tem). Immunoblot analysis of the indicated proteins. One of 3 experiments is shown.

(B) IMR90 cells expressing BRAF^{V600E} alone or in combination with an shRNA targeting p16 (shp16) and treated with temsirolimus (Tem). Immunoblot analysis of the indicated proteins. One of 3 experiments is shown.

(C and D) Deoxyribonucleotide analysis in the RRM2 (C) and BRAF^{V600E} (D) models. n > 3/group; 1 of at least 3 experiments is shown. Data represent mean ± SEM. *p < 0.05.

(E) Same as (A). SA-β-Gal activity, BrdU incorporation, and colony formation (CF). One of 3 experiments is shown. Scale bar, 10 μm.

(F) Quantification of SA-β-Gal activity in (E). n = 3/group; 1 of 3 experiments is shown. Data represent mean ± SEM. *p < 0.001.

(G) Quantification of BrdU incorporation in (E). n = 3/group; 1 of 3 experiments is shown. Data represent mean ± SEM. *p < 0.001.

(H) Quantification of colony formation in (E). n = 3/group; one of 3 experiments is shown. Data represent mean ± SEM. *p < 0.001.

(legend continued on next page)

nucleotides (Figures 1K and 1L). Interestingly, we observed an increase in RRM2B in shRRM2/shp16 cells (Figures S1L and S1M), which is likely how these cells reduce nucleoside diphosphates and nucleoside triphosphates (NDPs/NTPs) to dNDPs/dNTPs. Excitingly, further metabolite analysis demonstrated that nucleotides were also significantly increased upon p16 knockdown in these models (Figures 1M, 1N, and S1N), suggesting that the increase in deoxyribonucleotides is not simply due to increased RRM2B or the proportion of cells in S phase. Together, these data indicate that p16 depletion increases both nucleotide and deoxyribonucleotide synthesis to bypass senescence.

p16 Knockdown Activates mTORC1 to Bypass Senescence and Increase Nucleotide Synthesis

We next aimed to determine the underlying mechanism of nucleotide synthesis upon p16 knockdown. p16 inhibits E2F-mediated transcription in part through regulating the retinoblastoma protein (RB)-E2F interaction (Sherr, 2001). Gene set enrichment analysis (GSEA) of our RNA sequencing (RNA-seq) (GEO: GSE133660) did not show terms related to nucleotide synthesis (Data S1). However, GSEA showed an enrichment in the mTORC1 signaling pathway upon p16 knockdown, which was confirmed by reverse phase protein array (RPPA) (Data S1). Underscoring the pathological relevance of our findings, the mTORC1 signaling pathway was also enriched in melanoma compared with nevi in two independent datasets (Kabbarah et al., 2010; Talantov et al., 2005) (Data S1). Previous studies demonstrated that mTORC1 increases nucleotide synthesis (Ben-Sahra et al., 2013, 2016), suggesting that this may be the mechanism by which the loss of p16 increases nucleotides. We confirmed the activation of mTORC1 signaling by assessing the increased phosphorylation of S6K and 4E-BP1 (Figures 2A and 2B) as well as by mTORC1 localization at the lysosomal membrane (Figures S2A and S2B). Inhibition of mTORC1 with temsirolimus significantly decreased nucleotides and deoxyribonucleotides and suppressed senescence bypass in both models (Figures 2A–2L and Data S2), whereas it had no effect on parental cell proliferation (Figure S2C). Together, these data demonstrate that activation of mTORC1 downstream of p16 loss drives the observed increase in nucleotides, which is required for senescence bypass.

mTORC1 is a master regulator of translation (Ma and Blenis, 2009; Nandagopal and Roux, 2015). Interestingly, increased expression of leading-edge genes associated with the “translation” GSEA term (Data S1) significantly co-occurred with alterations in *CDKN2A* in multiple cancer types and was associated with worse overall survival (Figures S2D and S2E). Additionally, knockdown of p16 in cancer cell lines with wild-type p16 expression increased phosphorylation of S6K and 4E-BP1 (Figure 2M). Consistently, low p16 expression increased the sensitivity to

mTORC1 inhibition (Figures 2N, S2F, and S2G). Together, these data indicate that mTORC1 activation also occurs in cancer cells upon p16 suppression and correlates with increased sensitivity to mTORC1 inhibition.

Finally, we aimed to determine whether increased mTORC1 signaling is dependent on RB. Although RB knockdown suppressed BRAF^{V600E}-induced senescence, it did not increase p-S6K or p-4EBP1 in any of the models tested (Figures S2H–S2N). Consistently, mTOR signaling pathways were not enriched in an independent dataset of RB knockdown in senescence (Data S1) (Chicas et al., 2010). This suggests that the upregulation of mTORC1 activity is not a cell-cycle-dependent phenomenon and that it occurs in an RB-independent pathway. Together, these data demonstrate that activation of mTORC1 signaling upon p16 suppression is critical for nucleotide synthesis and senescence bypass in an RB-independent manner.

mTORC1 Activation by p16 Knockdown Increases Translation of Ribose-5-Phosphate Isomerase A and Promotes Nucleotide Synthesis through the Pentose Phosphate Pathway

Previous reports showed that mTORC1 upregulates purine and pyrimidine metabolism through ATF4-*MTHFD2* and CAD, respectively (Ben-Sahra et al., 2013, 2016). We did not observe an increase in *MTHFD2* transcription or CAD phosphorylation after p16 knockdown (Figures S3A and S3B). As mTORC1 activity increases translation (Ma and Blenis, 2009), we aimed to determine whether the observed increase in mTORC1-mediated nucleotide synthesis upon p16 suppression increases translation of transcripts involved in nucleotide synthesis. We performed polysome fractionation (Figure S3C) followed by RT-qPCR analysis of transcripts involved in nucleotide synthesis and related anaplerotic pathways. Our results reveal a number of transcripts whose abundance shifted from the light to the heavy polysome fraction upon p16 knockdown (Figure 3A; Table S1), including *EEF2*, which is known to be translationally regulated by mTORC1 (Thoreen et al., 2012) (Figure S3D). Interestingly, ribose-5-phosphate isomerase A (*RPIA*), an enzyme that synthesizes the ribose sugar backbone for both purines and pyrimidines (Lane and Fan, 2015) was the top hit (see STAR Methods) (Figure 3A; Table S1). Although MYC increases *RPIA* transcription (Santana-Codina et al., 2018), we did not observe changes in *RPIA* gene expression or MYC protein expression in these cells (Figures 3B and S3E). Consistent with the idea that mTORC1 regulates *RPIA* translation, *RPIA* protein expression was increased after p16 knockdown and decreased upon mTORC1 inhibition with temsirolimus (Figures 3C and 3D). Increased *RPIA* protein expression was also observed in 7 isogenic cancer cell lines upon p16 suppression (Figures 3E and 3F) and decreased upon knockdown of RPTOR (Figure S3F).

(I) Same as (B). SA- β -Gal activity, BrdU incorporation, and colony formation (CF). One of 3 experiments is shown. Scale bar, 10 μ m.

(J) Quantification of SA- β -Gal activity in (I). $n = 3/\text{group}$; 1 of 3 experiments is shown. Data represent mean \pm SEM. * $p < 0.02$.

(K) Quantification of BrdU incorporation in (I). $n = 3/\text{group}$, 1 of 3 experiments is shown. Data represent mean \pm SEM. * $p < 0.001$.

(L) Quantification of colony formation in (I). $n = 3/\text{group}$, 1 of 3 experiments is shown. Data represent mean \pm SEM. * $p < 0.001$.

(M) Immunoblot analysis of the indicated proteins in cancer cell lines with wild-type p16 expressing shp16. One of at least 2 experiments is shown.

(N) Same as (M) but cells were treated with temsirolimus. $n = 3/\text{group}$; 1 of 2 experiments is shown.

See also Figure S2 and Data S1 and S2.




Figure 3. Suppression of p16 Increases mTORC1-Mediated RPIA Translation and Nucleotide Synthesis by the Pentose Phosphate Pathway

(A and B) IMR90 cells expressing shRNA targeting RRM2 (shRRM2) alone or in combination with an shRNA targeting p16 (shp16). (A) Heatmap of light and heavy fractions from polysome profiling (see Table S1 for raw data). This experiment was performed once with 3 technical replicates. (B) Total RPIA expression from RNA-seq. Data represent mean \pm SEM. ns, not significant. (C) Same as (A) but cells were treated with temsirolimus (Tem). Immunoblot analysis of the indicated proteins. One of 3 experiments is shown. (D) IMR90 cells expressing BRAF^{V600E} alone or in combination with shp16 and treated with temsirolimus (Tem). Immunoblot analysis of the indicated proteins. One of 3 experiments is shown. (E) CDKN2A expression in the indicated cancer cell lines with wild-type p16 expression expressing shp16. *p < 0.006. (F) Same as (E) but immunoblot analysis of RPIA. One of at least 2 experiments is shown. (G) Percentage of RPIA mRNA abundance in polysome fractions in the indicated conditions. *p < 0.05. (H–J) SKMel28 and HT-29 cell expressing shp16 treated with Torin 1. (H) Immunoblot analysis of the indicated proteins. (I) Percentage of RPIA mRNA abundance in polysome fractions.

(legend continued on next page)

Inhibition of mTORC1 with temsirolimus shifted the *RPIA* mRNA from the heavy to the light polysome fraction, whereas it did not decrease total *RPIA* mRNA expression (Figures 3G and S3G). To confirm the direct role of mTORC1 in *RPIA* translation upon p16 knockdown, we performed polysome fractionation after 3 h of Torin 1 treatment (similar to Thoreen et al., 2012). Torin 1 inhibited mTORC1 activity and *RPIA* translation (Figures 3H and 3I). Additionally, knockdown of p16 increased 35S-methionine and cysteine incorporation into *RPIA*, which was decreased by Torin 1 treatment (Figure 3J). Consistent with increased *RPIA* protein expression, total ribose-5-phosphate (R5P) was increased upon p16 knockdown and decreased by inhibition of mTORC1 (Figures 3K and 3L). Finally, stable isotope labeling using U-¹³C glucose demonstrated an increase in the M+5 fraction of R5P and multiple nucleotides upon p16 knockdown, which was abrogated by temsirolimus treatment (Figures 3M–3P; Data S2). Taken together, these data demonstrate that knockdown of p16 increases mTORC1-mediated translation of *RPIA* to fuel R5P and nucleotide synthesis.

R5P Isomerase A Is a Metabolic Vulnerability of p16-Low Cells *In Vitro* and *In Vivo*

To determine whether *RPIA* is necessary for proliferation of cells with p16 knockdown, we depleted *RPIA* by using two independent short hairpin RNAs (shRNAs). Our data indicate that *RPIA* is necessary for proliferation of p16 knockdown cells as it induced senescence in all cell models tested (Figures 4A–4I, S4A–S4F, and S5A–S5F). Knockdown of *RPIA* alone had no effect on parental cells (Figures S4A–S4F). We did not observe a marked increase in cell death (Figure S5G), suggesting that the observed loss of proliferation is likely due to the senescence-associated cell cycle arrest. Similar results were observed *in vivo*, where knockdown of *RPIA* inhibited tumor growth in HT-29 cells with shp16 but not controls (Figures 4J–4L). Consistent with our *in vitro* data, *LMNB1* was decreased only in shp16/sh*RPIA* tumors (Figure 4M). Although there was a decrease in *CCNA2* upon *RPIA* knockdown alone, the difference was significantly larger in shp16/sh*RPIA* compared to shp16 alone tumors (Figure 4N). Together, these data indicate that *RPIA*-mediated increased nucleotide synthesis is necessary for cancer cell proliferation both *in vitro* and *in vivo* and that suppression of *RPIA* may be a target for cancers with low p16 expression.

DISCUSSION

The absence of p16 predisposes cells to tumorigenesis (LaPak and Burd, 2014), and its expression is low or null in many human cancers (Cerami et al., 2012; Gao et al., 2013). There is currently no approved targeted therapy for p16-low tumors (Otto and

Sicinski, 2017). Therefore, delineating the molecular mechanisms downstream of p16 suppression is critical to identify new therapeutics for these patients. Although the role of p16 loss in deregulating the cell cycle has been known for decades (Sherr, 2001), its role in metabolism is unclear. In this study, we found that mTORC1 signaling activation upon p16 suppression increases nucleotide synthesis. Mechanistically, we found mTORC1 activity leads to increased translation of *RPIA* and glucose flux through the pentose phosphate pathway to increase nucleotide levels. Suppression of p16 in cancer cells also leads to increased mTORC1 activity and increased *RPIA* translation and protein expression, and these cells are more sensitive to mTORC1 inhibitors or *RPIA* suppression than p16 wild-type cells. Together, our results suggest that increased nucleotide metabolism by *RPIA* upregulation is a metabolic vulnerability of p16-null cancers.

Cancer cells reprogram metabolism to increase biomass needed for growth and proliferation (Pavlova and Thompson, 2016). Modulation of nucleotide and deoxyribonucleotide levels is critical for multiple cancer cell phenotypes, including for the repair of damaged DNA and to ensure rapid proliferation (Kohnken et al., 2015). We previously found that increased dNTPs, either through upregulation of RRM2 expression or loss of ATM, bypass senescence (Aird et al., 2013, 2015). Additionally, a recent paper found that metabolic reprogramming, including increased nucleotide levels, precedes tumor formation in a UVB-induced skin cancer model (Hosseini et al., 2018). Here, we show that the loss of p16 increases nucleotide synthesis through a mechanism mediated by mTORC1. Excitingly, activation of this pathway increased both nucleotides and deoxyribonucleotides. We observed an increase in the other ribonucleotide reductase R2 subunit RRM2B. RRM2B has been shown to play a role in mitochondrial dNTP synthesis and in response to DNA damage (Bourdon et al., 2007; Pontarin et al., 2012). Interestingly, RRM2B was increased in both shRRM2 alone and shRRM2/shp16 cells. This suggests that although RRM2B is likely important for reducing NDPs/NTPs to dNDPs/dNTPs in senescence bypass, its upregulation alone is not sufficient to produce dNDPs/dNTPs. Indeed, these data further support the notion that it is only when upstream nucleotides are also increased, such as when p16 is knocked down, that the expression of RRM2B is critical for senescence bypass.

The canonical function of p16 is upstream of RB to affect E2F and the cell cycle (Sherr, 2001). We found that mTORC1 upregulation downstream of p16 knockdown is independent of RB in multiple cell types. There are an increasing number of studies reporting RB-independent functions of p16 (Al-Khalaf et al., 2013; Jenkins et al., 2011; Lee et al., 2013; Tyagi et al., 2017), suggesting that the non-canonical pathway of p16 loss needs to be

(J) Counts per million (CPM) after [³⁵S]-methionine and cysteine labeling and *RPIA* immunoprecipitation (IP). Data represent the percentage of CPM normalized by the excised band weight. One of 2 experiments is shown.

(K and L) Ribose-5-phosphate (R5P) abundance in the RRM2 (K) and BRAF^{V600E} (L) models. n > 3/group; 1 of at least 3 experiments is shown. Data represent mean ± SEM. *p < 0.01.

(M and N) R5P M+5 in the RRM2 (M) and BRAF^{V600E} (N) models. n > 3/group; 1 of at least 3 experiments is shown. Data represent mean ± SEM. *p < 0.05.

(O and P) dTTP M+5 and UTP M+5 in the RRM2 (O) and BRAF^{V600E} (P) models. n > 3/group; 1 of at least 3 experiments is shown. Data represent mean ± SEM. *p < 0.03; ND, not detected.

See also Figure S3, Data S2, and Table S1.




Figure 4. Inhibition of RPIA Is a Metabolic Vulnerability for Cells with Low p16

(A–E) IMR90 cells expressing BRAF^{V600E} alone or in combination with 2 independent shRNAs targeting RPIA (shRPIA).

(A) Immunoblot analysis of the indicated proteins. One of 3 experiments is shown.

(B) SA- β -Gal activity, BrdU incorporation, and colony formation. One of 3 experiments is shown. Scale bar, 10 μ m.

(C) Quantification of SA- β -Gal activity in (B). $n = 3$ /group; 1 of 3 experiments is shown. Data represent mean \pm SEM. * $p < 0.001$.

(D) Quantification of BrdU incorporation in (B). $n = 3$ /group; 1 of 3 experiments is shown. Data represent mean \pm SEM. * $p < 0.02$.

(E) Quantification of colony formation in (B). $n = 3$ /group; 1 of 3 experiments is shown. Data represent mean \pm SEM. * $p < 0.001$.

(F–H) ES2 (F), HT-29 (G), and PATU8902 (H) cancer cell lines with wild-type p16 expression expressing shRPIA alone or in combination with shp16. SA- β -Gal activity, BrdU incorporation, and colony formation (CF). $n = 3$ /group; 1 of at least 2 experiments is shown. Scale bar, 10 μ m. Data represent mean \pm SEM. * $p < 0.05$ versus shp16 alone.

(I) *CCNA2* and *LMNB1* fold change in the indicated cells. One of at least 2 experiments is shown. Data represent mean \pm SD. * $p < 0.05$ versus shp16 alone.

(J) Tumor growth curve of the indicated groups.

(legend continued on next page)

explored to identify both mechanistic underpinnings of RB-independent functions and novel therapies for cancer patients with p16-null tumors. As knockdown of p16 increased mTORC1 at the lysosomal membrane, it is possible that this pathway affects amino acid transporters and/or uptake. Additionally, a previous report in a mouse model of melanomagenesis also found increased mTORC1 signaling upon *Cdkn2a* knockout due to miR-99/100 expression (Damsky et al., 2015). Finally, it is possible that the effect of p16 knockdown is through cyclin D1/CDK4, which has previously been shown to phosphorylate TSC2, thereby activating mTORC1 signaling (Goel et al., 2016). Further research is needed to understand the connection between the loss of p16 and the activation of mTORC1.

mTORC1 is a master regulator of metabolism by coordinating metabolite availability through translational control of metabolic enzymes (Iurlaro et al., 2014; Zoncu et al., 2011). Recent studies have linked mTORC1 to both purine and pyrimidine synthesis (Ben-Sahra et al., 2013, 2016). Our results indicate that suppression of p16 increases mTORC1-mediated translation of *RPIA*. Previous studies have shown that *RPIA* is transcriptionally regulated by mTORC1 signaling (Düvel et al., 2010) or MYC (Santana-Codina et al., 2018). We did not observe a transcriptional increase in *RPIA* or MYC upregulation in our model, suggesting that *RPIA* upregulation is context-dependent. Consistent with our results, a recent paper showed that total *RPIA* mRNA expression is not significantly decreased after 24 h of Torin 1 treatment (Park et al., 2017). Instead, our data demonstrate that *RPIA* is directly translationally regulated by mTORC1 as inhibition of mTORC1 with a short Torin 1 treatment decreased *RPIA* transcripts in the heavy polysome fraction as well as *RPIA* protein expression. Consistent with the idea that our results are MYC-independent, a previous publication demonstrated that *MYC* mRNA is resistant to Torin 1 inhibition (Thoreen et al., 2012). Taken together, these data demonstrate that the observed increase in *RPIA* protein upon the loss of p16 is mediated through mTORC1-specific translation.

Cell cycle inhibitors are currently being tested in the clinic for tumors with deletions or mutations in *CDKN2A* (<http://clinicaltrials.gov>); however, no US Food and Drug Administration (FDA)-approved therapy currently exists for this subset of patients. Moreover, our data and others demonstrate that p16 may have functions outside of the cell cycle and RB (Al-Khalaf et al., 2013; Jenkins et al., 2011; Lee et al., 2013; Tyagi et al., 2017), suggesting that these inhibitors may not be efficacious in these patients. Excitingly, our results with p16 suppression open up a metabolic vulnerability through activation of mTORC1-mediated nucleotide metabolism. Indeed, we found that isogenic p16-null cells are more sensitive to temsirolimus or suppression of *RPIA* both *in vitro* and *in vivo*. *RPIA* inhibition has been shown to limit the growth of *Kras*^{G12D} cell lines and xenografted tumors (Santana-Codina et al., 2018; Ying et al., 2012).

Our results demonstrate that *RPIA* expression could also be exploited as a metabolic target in p16-null cancers.

In conclusion, our study provides a molecular effect of p16 loss whereby mTORC1 signaling is activated to increase nucleotide metabolism. This is different, yet likely linked, to its canonical role in cell cycle regulation. These mechanistic insights have broad implications for understanding pro-tumorigenic metabolism. Moreover, this study provides a metabolic vulnerability for p16-low cancer cells, which may be exploited for therapy.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- LEAD CONTACT AND MATERIALS AVAILABILITY
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
 - Cell Lines
 - Mice
- METHOD DETAILS
 - Lentiviral and retroviral packaging and infection
 - RNA-Sequencing and Analysis
 - Reverse Phase Protein Array (RPPA)
 - Gene set enrichment analysis (GSEA)
 - Polysome fractionation
 - RT-qPCR
 - [³⁵S]-methionine/cysteine incorporation followed by IP
 - Senescence and proliferation assays
 - Temsirolimus half maximal inhibitory concentration (IC₅₀) assay
 - Immunofluorescence
 - Western blotting
 - Nucleotide Analysis by LC-HRMS
 - Glucose labeling and analysis
 - Flow Cytometry
 - Murine tumor model
- QUANTIFICATION AND STATISTICAL ANALYSIS
- DATA AND CODE AVAILABILITY

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.celrep.2019.07.084>.

ACKNOWLEDGMENTS

We would like to acknowledge Dr. Alice Soragni (UCLA), Dr. Kristin Eckert and Dr. Nadine Hempel (Penn State College of Medicine), Dr. Gina DeNicola (Moffitt Cancer Center), and Dr. Rugang Zhang (The Wistar Institute) for providing cell lines. We would like to thank Drs. Juan Andres Melendez and Robert P. Feehan for providing helpful discussion. This work was supported by grants from the NIH (F31CA236372 to E.S.D., P50CA174523 and U54CA224070 to

(K) Representative images of mice from each group. Tumors are outlined in red.

(L) Tumor volume at day 26 post-implantation. *p = 0.0414; ns, not significant.

(M) *LMNB1* expression in the indicated tumors. ns, not significant.

(N) *CCNA2* expression in the indicated tumors.

See also Figures S4 and S5.

M.H., R01DK13499 and R01K156548 to S.R.K., K22ES026235 and R01GM132261 to N.W.S., and R00CA194309 to K.M.A.); the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (to M.H.); the W.W. Smith Charitable Trust (to K.M.A.); and the Penn State Cancer Institute Postdoctoral Fellowship (to R.B.). The RPPA Core Facility is funded by NCI P30CA16672.

AUTHOR CONTRIBUTIONS

Conceptualization, R.B. and K.M.A.; Methodology, R.K., Y.I., and N.W.S.; Investigation, R.B., C.-W.C., E.S.D., K.E.L., R.K., N.M., M.N., M.T.D., H.J., M.Z., L.K., H.L., Y.I., N.W.S., and K.M.A.; Resources, G.Z., R.G., G.R., J.I.W., M.H., and D.J.D.; Writing, R.B., N.W.S., and K.M.A.; Visualization, R.B., C.-W.C., R.K., N.S.W., and K.M.A.; Supervision, M.H., Y.L., G.B.M., G.R., J.I.W., S.R.K., D.J.D., N.W.S., and K.M.A.; Funding Acquisition, G.B.M., M.H., N.W.S., and K.M.A.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: January 16, 2019

Revised: July 1, 2019

Accepted: July 23, 2019

Published: August 20, 2019

REFERENCES

- Aird, K.M., and Zhang, R. (2014). Metabolic alterations accompanying oncogene-induced senescence. *Mol. Cell. Oncol.* *1*, e963481.
- Aird, K.M., and Zhang, R. (2015). Nucleotide metabolism, oncogene-induced senescence and cancer. *Cancer Lett.* *356* (2 Pt A), 204–210.
- Aird, K.M., Zhang, G., Li, H., Tu, Z., Bitler, B.G., Garipov, A., Wu, H., Wei, Z., Wagner, S.N., Herlyn, M., and Zhang, R. (2013). Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. *Cell Rep.* *3*, 1252–1265.
- Aird, K.M., Worth, A.J., Snyder, N.W., Lee, J.V., Sivanand, S., Liu, Q., Blair, I.A., Wellen, K.E., and Zhang, R. (2015). ATM couples replication stress and metabolic reprogramming during cellular senescence. *Cell Rep.* *11*, 893–901.
- Akbani, R., Ng, P.K., Werner, H.M., Shahmoradgoli, M., Zhang, F., Ju, Z., Liu, W., Yang, J.Y., Yoshihara, K., Li, J., et al. (2014). A pan-cancer proteomic perspective on The Cancer Genome Atlas. *Nat. Commun.* *5*, 3887.
- Al-Khalaf, H.H., Mohideen, P., Nallar, S.C., Kalvakolanu, D.V., and Abousekhra, A. (2013). The cyclin-dependent kinase inhibitor p16INK4a physically interacts with transcription factor Sp1 and cyclin-dependent kinase 4 to transactivate microRNA-141 and microRNA-146b-5p spontaneously and in response to ultraviolet light-induced DNA damage. *J. Biol. Chem.* *288*, 35511–35525.
- Ben-Sahra, I., Howell, J.J., Asara, J.M., and Manning, B.D. (2013). Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. *Science* *339*, 1323–1328.
- Ben-Sahra, I., Hoxhaj, G., Ricoult, S.J.H., Asara, J.M., and Manning, B.D. (2016). mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. *Science* *351*, 728–733.
- Bennecke, M., Kriegl, L., Bajbouj, M., Retzlaff, K., Robine, S., Jung, A., Arkan, M.C., Kirchner, T., and Greten, F.R. (2010). Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. *Cancer Cell* *18*, 135–146.
- Bennett, D.C. (2016). Genetics of melanoma progression: the rise and fall of cell senescence. *Pigment Cell Melanoma Res.* *29*, 122–140.
- Boissan, M., Schlattner, U., and Lacombe, M.L. (2018). The NDPK/NME superfamily: state of the art. *Lab. Invest.* *98*, 164–174.
- Bourdon, A., Minai, L., Serre, V., Jais, J.P., Sarzi, E., Aubert, S., Chrétien, D., de Lonlay, P., Paquis-Fluckinger, V., Arakawa, H., et al. (2007). Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. *Nat. Genet.* *39*, 776–780.
- Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A.H., Schlegelberger, B., Stein, H., Dörken, B., Jenuwein, T., and Schmitt, C.A. (2005). Oncogene-induced senescence as an initial barrier in lymphoma development. *Nature* *436*, 660–665.
- Caldwell, M.E., DeNicola, G.M., Martins, C.P., Jacobetz, M.A., Maitra, A., Hruban, R.H., and Tuveson, D.A. (2012). Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer. *Oncogene* *31*, 1599–1608.
- Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. (2012). The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* *2*, 401–404.
- Chicas, A., Wang, X., Zhang, C., McCurrach, M., Zhao, Z., Mert, O., Dickins, R.A., Narita, M., Zhang, M., and Lowe, S.W. (2010). Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. *Cancer Cell* *17*, 376–387.
- Damsky, W., Micevic, G., Meeth, K., Muthusamy, V., Curley, D.P., Santhanakrishnan, M., Erdelyi, I., Platt, J.T., Huang, L., Theodosakis, N., et al. (2015). mTORC1 activation blocks BravF600E-induced growth arrest but is insufficient for melanoma formation. *Cancer Cell* *27*, 41–56.
- Dankort, D., Filenova, E., Collado, M., Serrano, M., Jones, K., and McMahon, M. (2007). A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. *Genes Dev.* *21*, 379–384.
- Dimri, G.P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E.E., Linskens, M., Rubelj, I., Pereira-Smith, O., et al. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. *Proc. Natl. Acad. Sci. USA* *92*, 9363–9367.
- Dörr, J.R., Yu, Y., Milanovic, M., Beuster, G., Zasada, C., Däbritz, J.H., Lisec, J., Lenze, D., Gerhardt, A., Schleicher, K., et al. (2013). Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. *Nature* *501*, 421–425.
- Düvel, K., Yecies, J.L., Menon, S., Raman, P., Lipovsky, A.I., Souza, A.L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010). Activation of a metabolic gene regulatory network downstream of mTOR complex 1. *Mol. Cell* *39*, 171–183.
- Enot, D.P., Vacchelli, E., Jacquolot, N., Zitvogel, L., and Kroemer, G. (2018). TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves. *Oncolmmunology* *7*, e1462431.
- Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci. Signal.* *6*, p11.
- Goel, V.K., Ibrahim, N., Jiang, G., Singhal, M., Fee, S., Flotte, T., Westmoreland, S., Haluska, F.S., Hinds, P.W., and Haluska, F.G. (2009). Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. *Oncogene* *28*, 2289–2298.
- Goel, S., Wang, Q., Watt, A.C., Tolaney, S.M., Dillon, D.A., Li, W., Ramm, S., Palmer, A.C., Yuzugullu, H., Varadan, V., et al. (2016). Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. *Cancer Cell* *29*, 255–269.
- Guo, L., Worth, A.J., Mesaros, C., Snyder, N.W., Glickson, J.D., and Blair, I.A. (2016). Diisopropylethylamine/hexafluoroisopropanol-mediated ion-pairing ultra-high-performance liquid chromatography/mass spectrometry for phosphate and carboxylate metabolite analysis: utility for studying cellular metabolism. *Rapid Commun. Mass Spectrom.* *30*, 1835–1845.
- Haferkamp, S., Becker, T.M., Scurr, L.L., Kefford, R.F., and Rizos, H. (2008). p16INK4a-induced senescence is disabled by melanoma-associated mutations. *Aging Cell* *7*, 733–745.
- Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. *Cell* *144*, 646–674.
- Hernandez-Segura, A., Nehme, J., and Demaria, M. (2018). Hallmarks of Cellular Senescence. *Trends Cell Biol.* *28*, 436–453.

- Hosseini, M., Dousset, L., Mahfouf, W., Serrano-Sanchez, M., Redonnet-Vernhet, I., Mesli, S., Kasraian, Z., Obre, E., Bonneau, M., Claverol, S., et al. (2018). Energy Metabolism Rewiring Precedes UVB-Induced Primary Skin Tumor Formation. *Cell Rep.* **23**, 3621–3634.
- Iurlaro, R., León-Annicchiarico, C.L., and Muñoz-Pinedo, C. (2014). Regulation of cancer metabolism by oncogenes and tumor suppressors. *Methods Enzymol.* **542**, 59–80.
- Jenkins, N.C., Liu, T., Cassidy, P., Leachman, S.A., Boucher, K.M., Goodson, A.G., Samadashwily, G., and Grossman, D. (2011). The p16(INK4A) tumor suppressor regulates cellular oxidative stress. *Oncogene* **30**, 265–274.
- Kabbarah, O., Nogueira, C., Feng, B., Nazarian, R.M., Bosenberg, M., Wu, M., Scott, K.L., Kwong, L.N., Xiao, Y., Cordon-Cardo, C., et al. (2010). Integrative genome comparison of primary and metastatic melanomas. *PLoS One* **5**, e10770.
- Kohnken, R., Kodigepalli, K.M., and Wu, L. (2015). Regulation of deoxynucleotide metabolism in cancer: novel mechanisms and therapeutic implications. *Mol. Cancer* **14**, 176.
- Kriegel, L., Neumann, J., Vieth, M., Greten, F.R., Reu, S., Jung, A., and Kirchner, T. (2011). Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. *Mod. Pathol.* **24**, 1015–1022.
- Kuskovsky, R., Buj, R., Xu, P., Hofbauer, S., Doan, M.T., Jiang, H., Bostwick, A., Mesaros, C., Aird, K.M., and Snyder, N.W. (2019). Simultaneous isotope dilution quantification and metabolic tracing of deoxyribonucleotides by liquid chromatography high resolution mass spectrometry. *Anal. Biochem.* **568**, 65–72.
- Lane, A.N., and Fan, T.W.M. (2015). Regulation of mammalian nucleotide metabolism and biosynthesis. *Nucleic Acids Res.* **43**, 2466–2485.
- LaPak, K.M., and Burd, C.E. (2014). The molecular balancing act of p16(INK4a) in cancer and aging. *Mol. Cancer Res.* **12**, 167–183.
- Lee, M.H., Choi, B.Y., Cho, Y.Y., Lee, S.Y., Huang, Z., Kundu, J.K., Kim, M.O., Kim, D.J., Bode, A.M., Surh, Y.J., and Dong, Z. (2013). Tumor suppressor p16(INK4a) inhibits cancer cell growth by downregulating eEF1A2 through a direct interaction. *J. Cell Sci.* **126**, 1744–1752.
- Li, J., Poi, M.J., and Tsai, M.D. (2011). Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer. *Biochemistry* **50**, 5566–5582.
- Lynch, C.J., Kimball, S.R., Xu, Y., Salzberg, A.C., and Kawasawa, Y.I. (2015). Global deletion of BCATm increases expression of skeletal muscle genes associated with protein turnover. *Physiol. Genomics* **47**, 569–580.
- Ma, X.M., and Blenis, J. (2009). Molecular mechanisms of mTOR-mediated translational control. *Nat. Rev. Mol. Cell Biol.* **10**, 307–318.
- Mannava, S., Moparthy, K.C., Wheeler, L.J., Natarajan, V., Zucker, S.N., Fink, E.E., Im, M., Flanagan, S., Burhans, W.C., Zeitouni, N.C., et al. (2013). Depletion of Deoxyribonucleotide Pools Is an Endogenous Source of DNA Damage in Cells Undergoing Oncogene-Induced Senescence. *Am. J. Pathol.* **182**, 142–151.
- Michaloglou, C., Vredeveld, L.C., Soengas, M.S., Denoyelle, C., Kuilman, T., van der Horst, C.M., Majoor, D.M., Shay, J.W., Mooi, W.J., and Peepers, D.S. (2005). BRAFE600-associated senescence-like cell cycle arrest of human naevi. *Nature* **436**, 720–724.
- Nandagopal, N., and Roux, P.P. (2015). Regulation of global and specific mRNA translation by the mTOR signaling pathway. *Translation (Austin)* **3**, e983402.
- Otto, T., and Sicinski, P. (2017). Cell cycle proteins as promising targets in cancer therapy. *Nat. Rev. Cancer* **17**, 93–115.
- Panda, A.C., Martindale, J.L., and Gorospe, M. (2017). Polysome Fractionation to Analyze mRNA Distribution Profiles. *Bio. Protoc.* **7**, e2126.
- Park, Y., Reyna-Neyra, A., Philippe, L., and Thoreen, C.C. (2017). mTORC1 Balances Cellular Amino Acid Supply with Demand for Protein Synthesis through Post-transcriptional Control of ATF4. *Cell Rep.* **19**, 1083–1090.
- Pavlova, N.N., and Thompson, C.B. (2016). The Emerging Hallmarks of Cancer Metabolism. *Cell Metab.* **23**, 27–47.
- Pérez-Mancera, P.A., Young, A.R., and Narita, M. (2014). Inside and out: the activities of senescence in cancer. *Nat. Rev. Cancer* **14**, 547–558.
- Pontarin, G., Ferraro, P., Bee, L., Reichard, P., and Bianchi, V. (2012). Mammalian ribonucleotide reductase subunit p53R2 is required for mitochondrial DNA replication and DNA repair in quiescent cells. *Proc. Natl. Acad. Sci. USA* **109**, 13302–13307.
- Santana-Codina, N., Roeth, A.A., Zhang, Y., Yang, A., Mashadova, O., Asara, J.M., Wang, X., Bronson, R.T., Lyssiotis, C.A., Ying, H., and Kimmelman, A.C. (2018). Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. *Nat. Commun.* **9**, 4945.
- Sarkisian, C.J., Keister, B.A., Stairs, D.B., Boxer, R.B., Moody, S.E., and Chodosh, L.A. (2007). Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. *Nat. Cell Biol.* **9**, 493–505.
- Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell* **88**, 593–602.
- Shain, A.H., Yeh, I., Kovalyshyn, I., Sriharan, A., Talevich, E., Gagnon, A., Dummer, R., North, J., Pincus, L., Ruben, B., et al. (2015). The Genetic Evolution of Melanoma from Precursor Lesions. *N. Engl. J. Med.* **373**, 1926–1936.
- Sherr, C.J. (2001). The INK4a/ARF network in tumour suppression. *Nat. Rev. Mol. Cell Biol.* **2**, 731–737.
- Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA* **102**, 15545–15550.
- Talantov, D., Mazumder, A., Yu, J.X., Briggs, T., Jiang, Y., Backus, J., Atkins, D., and Wang, Y. (2005). Novel genes associated with malignant melanoma but not benign melanocytic lesions. *Clin. Cancer Res.* **11**, 7234–7242.
- Thoreen, C.C., Chantranupong, L., Keys, H.R., Wang, T., Gray, N.S., and Sabatini, D.M. (2012). A unifying model for mTORC1-mediated regulation of mRNA translation. *Nature* **485**, 109–113.
- Trefely, S., Ashwell, P., and Snyder, N.W. (2016). FluxFix: automatic isotopologue normalization for metabolic tracer analysis. *BMC Bioinformatics* **17**, 485.
- Tyagi, E., Liu, B., Li, C., Liu, T., Rutter, J., and Grossman, D. (2017). Loss of p16^{INK4A} stimulates aberrant mitochondrial biogenesis through a CDK4/Rb-independent pathway. *Oncotarget* **8**, 55848–55862.
- Uphoff, C.C., and Drexler, H.G. (2005). Detection of mycoplasma contaminations. *Methods Mol. Biol.* **290**, 13–23.
- Wiley, C.D., and Campisi, J. (2016). From Ancient Pathways to Aging Cells—Connecting Metabolism and Cellular Senescence. *Cell Metab.* **23**, 1013–1021.
- Yaswen, P., and Campisi, J. (2007). Oncogene-induced senescence pathways weave an intricate tapestry. *Cell* **128**, 233–234.
- Ying, H., Kimmelman, A.C., Lyssiotis, C.A., Hua, S., Chu, G.C., Fletcher-Sanankone, E., Locasale, J.W., Son, J., Zhang, H., Coloff, J.L., et al. (2012). Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. *Cell* **149**, 656–670.
- Zhang, Q., Wang, J., Deng, F., Yan, Z., Xia, Y., Wang, Z., Ye, J., Deng, Y., Zhang, Z., Qiao, M., et al. (2015). TqPCR: A Touchdown qPCR Assay with Significantly Improved Detection Sensitivity and Amplification Efficiency of SYBR Green qPCR. *PLoS One* **10**, e0132666.
- Zoncu, R., Efeyan, A., and Sabatini, D.M. (2011). mTOR: from growth signal integration to cancer, diabetes and ageing. *Nat. Rev. Mol. Cell Biol.* **12**, 21–35.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
RRM2	Santa Cruz Biotechnology	Cat # sc-398294
p16	Abcam	Cat# ab108349; RRID:AB_10858268
Vinculin	Sigma-Aldrich	Cat# V9131; RRID:AB_477629
S6K	Cell Signaling Technology	Cat# 2708; RRID:AB_390722
Phospho S6K (Thr389)	Cell Signaling Technology	Cat# 9234; RRID:AB_2269803
4E-BP1	Cell Signaling Technology	Cat# 9644; RRID: AB_2097841
Phospho 4E-BP1 (Ser65)	Cell Signaling Technology	Cat# 9451; RRID: AB_330947
RPTOR	Cell Signaling Technology	Cat# 2280; RRID: AB_561245
β -Actin	Sigma-Aldrich	Cat# A1978; RRID:AB_476692
RPIA	Abcam	Cat# ab181235
BRAF	Santa Cruz Biotechnology	Cat# sc-5284; RRID:AB_2721130
RB	BD Biosciences	Cat# 554136; RRID:AB_39525
CAD	Cell Signaling Technology	Cat# 11933; RRID: AB_2797772
Phospho CAD (Ser1859)	Cell Signaling Technology	Cat # 70307; RRID: AB_2799782
BrdU	Abcam	Cat# ab6326; RRID:AB_305426
mTOR	Cell Signaling Technology	Cat# 2983; RRID:AB_2105622
LAMP2	Santa Cruz Biotechnology	Cat# sc-18822; RRID:AB_626858
Anti-mouse HRP	Cell Signaling Technology	Cat# 7076; RRID:AB_330924
Anti-rabbit HRP	Cell Signaling Technology	Cat# 7074; RRID:AB_2099233
Anti-rat FITC	Jackson ImmunoResearch Labs	Cat# 712-095-150; RRID:AB_2340651
Anti-rabbit FITC	Jackson ImmunoResearch Labs	Cat# 711-095-152; RRID:AB_2315776
Anti-mouse Cy3	Jackson ImmunoResearch Labs	Cat# 715-165-150; RRID:AB_2340813
Bacterial and Virus Strains		
Stb3 Chemically Competent E.	Fisher Scientific	Cat# C737303
DH5 α Competent Cells	Fisher Scientific	Cat# 18265-017
Chemicals, Peptides, and Recombinant Proteins		
BrdU	Alfa Aesar	Cat # H27260
[³⁵ S]-methionine/cysteine	Perkin Elmer	Cat # NEG772
X-Gal	Sigma-Aldrich	Cat # B4252
D-Glucose-13C6	Sigma-Aldrich	Cat # 389374
Puromycin	GIBCO	Cat # A11138-02
Polybrene	Sigma-Aldrich	Cat # H9268
Propidium Iodide	Sigma-Aldrich	Cat# P4170
PureProteome™ Protein G Magnetic Beads	EMD Millipore	Cat # LSKMAGG10
cOmplete Mini EDTA-free	Roche	Cat # 11836170001
Crystal violet	Harleco	Cat # 192-12
DMEM 17	Corning	Cat# 10-017-CV
DMEM 13	Corning	Cat# 10-013-CV
RPMI	GIBCO	Cat# 11875093
DMEM w/o glucose or glutamine	Sigma-Aldrich	Cat# D5030
MEM/EBSS glutamine	HyClone	Cat# SH30024.01
MEM Nonessential Amino Acids	Corning	Cat# 25025CL
Glutagro	Corning	Cat# 25015CL

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Sodium Bicarbonate	Corning	Cat# 25035CL
Sodium Pyruvate	Corning	Cat# 25000CL
FBS	VWR	Cat# 16000-044
Charcoal stripped FBS	Sigma-Aldrich	Cat# F6765
Lipofectamine 2000	Invitrogen	Cat# 11668019
Trizol	Ambion	Cat# 15596018
Glutaraldehyde	Polysciences, Inc.	Cat# 01909
RNase Out	Invitrogen	Cat# 10777019
Formaldehyde	VWR	Cat# 0493
Paraformaldehyde	Sigma-Aldrich	Cat# 158127
Temsirolimus	Selleckchem	Cat# S1044
Torin 1	Med Chem Express	Cat# HY-13003
7AAD	Tonbo	Cat# 13-6993-T500
Optima LC-MS grade water	Thermo Fisher Scientific	Cat# W6-4
Optima LC-MS grade acetonitrile	Thermo Fisher Scientific	Cat# A955-4
Optima LC-MS grade methanol	Thermo Fisher Scientific	Cat# A456-4
1,1,1,3,3,3-hexafluoro 2-propanol (HFIP)	Sigma-Aldrich	Cat# 105228
Diisopropylethylamine (DIPEA)	Sigma-Aldrich	Cat# D125806
AMP standard	Sigma-Aldrich	Cat# 01930
dAMP standard	Sigma-Aldrich	Cat# D6375
ATP standard	Sigma-Aldrich	Cat# A26209
dATP standard	Sigma-Aldrich	Cat# D6500
dTMP standard	Sigma-Aldrich	Cat# T7004
dTTP standard	Sigma-Aldrich	Cat# T0251
CMP standard	Sigma-Aldrich	Cat# C1006
dCMP standard	Sigma-Aldrich	Cat# D7625
CTP standard	Sigma-Aldrich	Cat# C1506
dCTP standard	Sigma-Aldrich	Cat# D4635
UMP standard	Sigma-Aldrich	Cat# U6375
dUMP standard	Sigma-Aldrich	Cat# D3876
UDP standard	Sigma-Aldrich	Cat# 94330
UTP standard	Sigma-Aldrich	Cat# U6625
dUTP standard	Sigma-Aldrich	Cat# D4001
AMP- ¹³ C, ¹⁵ N standard	Sigma-Aldrich	Cat# 650676
dAMP- ¹³ C, ¹⁵ N standard	Sigma-Aldrich	Cat# 648620
ATP- ¹³ C, ¹⁵ N standard	Sigma-Aldrich	Cat# 645702
dATP- ¹³ C, ¹⁵ N standard	Sigma-Aldrich	Cat# 646237
TTP- ¹³ C, ¹⁵ N standard	Sigma-Aldrich	Cat# 646202
CTP- ¹³ C, ¹⁵ N standard	Sigma-Aldrich	Cat# 645699
dTPC- ¹³ C, ¹⁵ N standard	Sigma-Aldrich	Cat# 646229
UTP- ¹³ C, ¹⁵ N standard	Sigma-Aldrich	Cat# 645672
dTMP- ¹³ C, ¹⁵ N standard	Sigma-Aldrich	Cat# 648590
CMP- ¹³ C, ¹⁵ N standard	Sigma-Aldrich	Cat# 650692
UMP- ¹³ C, ¹⁵ N standard	Sigma-Aldrich	Cat# 651370
Critical Commercial Assays		
NucleoSpin RNA/Protein	Macherey-Nagel	Cat#740933
Deposited Data		
RNA-Seq	This paper	GEO: GSE133660

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Experimental Models: Cell Lines		
Fibroblasts: IMR90	ATCC	CCL-186
Fibroblasts: IMR90 shControl	This paper	N/A
Fibroblasts: IMR90 shRRM2	This paper	N/A
Fibroblasts: IMR90 shp16	This paper	N/A
Fibroblasts: IMR90 shRRM2/shp16	This paper	N/A
Fibroblasts: IMR90 shRRM2/shRB	This paper	N/A
Fibroblasts: IMR90 shRPIA	This paper	N/A
Fibroblasts: IMR90 shRRM2/shp16/shRPIA	This paper	N/A
Fibroblasts: IMR90 shRRM2/shp16/p16 OE	This paper	N/A
Fibroblasts: IMR90 Control	This paper	N/A
Fibroblasts: IMR90 BRAF ^{V600E}	This paper	N/A
Fibroblasts: IMR90 BRAF ^{V600E} /shp16	This paper	N/A
Fibroblasts: IMR90 BRAF ^{V600E} /shRB	This paper	N/A
BRAF ^{V600E} /shp16/shRPIA	This paper	N/A
Embryonic kidney: 293FT	Thermo Fisher	R70007
Embryonic kidney: Phoenix (QNX)	Dr. Gary Nolan	N/A
Skin: SKMel28	ATCC	HTB-72
Skin: SKMel28 shControl	This paper	N/A
Skin: SKMel28 shRPIA	This paper	N/A
Skin: SKMel28 shp16	This paper	N/A
Skin: SKMel28 shp16/shRPIA	This paper	N/A
Skin: SKMel28 shRB	This paper	N/A
Skin: SKMel28: shp16/shRPTOR #1	This paper	N/A
Skin: SKMel28: shp16/shRPTOR #2	This paper	N/A
Pancreas: PATU8902	G. DeNicola Laboratory	N/A
Pancreas: PATU8902 shControl	This paper	N/A
Pancreas: PATU8902 shRPIA	This paper	N/A
Pancreas: PATU8902 shp16	This paper	N/A
Pancreas: PATU8902 shp16/shRPIA	This paper	N/A
Ovary: ES-2	ATCC	Cr1-1978
Ovary: ES-2 shControl	This paper	N/A
Ovary: ES-2 shRPIA	This paper	N/A
Ovary: ES-2 shp16	This paper	N/A
Ovary: ES-2 shp16/shRPIA	This paper	N/A
Bladder: TCC-SUP	ATCC	HTB-5
Bladder: TCC-SUP shControl	This paper	N/A
Bladder: TCC-SUP shRPIA	This paper	N/A
Bladder: TCC-SUP shp16	This paper	N/A
Bladder: TCC-SUP shp16/shRPIA	This paper	N/A
Colon: SW620	ATCC	CCL-227
Colon: SW620 shControl	This paper	N/A
Colon: SW620 shRPIA	This paper	N/A
Colon: SW620 shp16	This paper	N/A
Colon: SW620 shp16/shRPIA	This paper	N/A
Colon: SW480	ATCC	CCL-228
Colon: SW480 shControl	This paper	N/A
Colon: SW480 shRPIA	This paper	N/A

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Colon: SW480 shp16	This paper	N/A
Colon: SW480 shp16/shRPIA	This paper	N/A
Colon: HT-29	ATCC	HTB-38
Colon: HT-29 shControl	This paper	N/A
Colon: HT-29 shRPIA	This paper	N/A
Colon: HT-29 shp16	This paper	N/A
Colon: HT-29 shp16/shRPIA	This paper	N/A
Skin: SKMel28 shRB	This paper	N/A
Skin: SKMel28: shp16/shRPTOR #1	This paper	N/A
Skin: SKMel28: shp16/shRPTOR #2	This paper	N/A
Experimental Models: Organisms/Strains		
C.B-17/ICRHsd-Prkdc scid mice	Envigo	182
Oligonucleotides		
RT-qPCR Primers (Listed in Table S2)	This paper	N/A
Software and Algorithms		
GSEA	Broad Institute	N/A
GraphPad Prism 7	N/A	N/A
IDT tool for primer design	Integrated DNA Technologies	N/A
Cufflinks	Version v.2.0.2	N/A

LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Katherine M. Aird (kaird@psu.edu). There are restrictions to the availability of the shRNA knockdown cell lines generated in this study since they were made with commercial reagents. These will only be distributed with permission of the commercial suppliers.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cell Lines

Normal diploid IMR90 human fibroblasts were cultured according to the ATCC in low oxygen (2% O₂) in DMEM (4.5 g/L glucose, Corning cat# 10-017-CV) with 10% FBS supplemented with L-glutamine, non-essential amino acids, sodium pyruvate, and sodium bicarbonate. Experiments were performed on IMR90 between population doubling #25-35. Melanoma (SKMel28), pancreatic (PATU8902), colorectal (HT-29, SW620, and SW480) tumor cells and lentiviral and retroviral packaging cells (293FT and Phoenix, respectively) were cultured in DMEM (Corning, cat# 10-013-CV) with 10% FBS. ES2 ovary tumor cell line was cultured in RPMI 1640 with 10% FBS. TCCSUP bladder cancer cell line was cultured in MEM/EBSS glutamine supplemented with 10% FBS. All cell lines were cultured in MycoZap and were routinely tested for mycoplasma as described in Uphoff and Drexler (2005). All tumor cell lines included in this work express wild-type *CDKN2A* according to TCGA (Cerami et al., 2012; Gao et al., 2013). According to ATCC, TCCSUP harbors a mutation in RB1. All cell lines were authenticated using STR Profiling (Genetica DNA Laboratories).

Mice

Two-month old male SCID mice were purchased from Charles River Laboratories. All mice were maintained in a HEPA-filtered ventilated rack system at the Penn State College of Medicine animal facility. Mice were housed up to 5 mice per cage and in a 12-hour light/dark cycle. All experiments with animals were performed in accordance with institutional guidelines approved by the Institutional Animal Care and Use Committee (IACUC) at the Penn State College of Medicine.

METHOD DETAILS

Lentiviral and retroviral packaging and infection

Retrovirus production and transduction were performed using the BBS/calcium chloride method (Aird et al., 2013). Phoenix cells (a gift from Dr. Gary Nolan, Stanford University) were used to package the infection viruses. Lentiviral constructs were transfected into 293FT cells using Lipofectamine 2000 (Thermo Fisher). Lentivirus was packaged using the ViraPower Kit (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions.

The basic IMR90 experiment timeline is delineated in [Figure S1A](#). Briefly, IMR90 cells were infected with pLKO.1 empty vector or pLKO.1-shRRM2, and 24 hours later cells were infected with pLKO.1 empty vector, pLKO.1-shp16 or pLKO.1-shRB. Cells were selected with puromycin (3 $\mu\text{g}/\text{mL}$) for 7 days. Alternatively, IMR90 cells were infected with pBABE control or pBABE BRAF^{V600E} vector and 24 hours later cells were infected with a second round of pBABE control or BRAF^{V600E} vector together with pLKO.1 empty vector, pLKO.1-shp16 or pLKO.1-shRB. Cells were selected with puromycin (3 $\mu\text{g}/\text{mL}$) for 7 days. Where indicated, cells were treated at day 4 with temsirolimus (0.5nM) or infected with pLKO.1-shRPIA. p16 rescue experiment was performed by simultaneous infection with pLKO.1-shp16 and pBABE-p16 overexpression plasmid. For single infections, cells were infected with the corresponding virus and selected in puromycin (1 $\mu\text{g}/\text{mL}$) for 7 days.

Tumor cell lines were infected with pLKO.1 empty vector, pLKO.1-shp16 or pLKO.1-shRB. Cells were selected with puromycin (1 $\mu\text{g}/\text{mL}$) for 4 days. Where indicated, cells were treated at day 4 with increasing concentrations of temsirolimus (0.07–50 μM) in 0.5% FBS for 5 days or infected with pLKO.1 shRPIA or pLKO.1-shRPTOR. For double infections, cells were selected in puromycin (3 $\mu\text{g}/\text{mL}$) for 4 additional days. For Torin 1 experiments, cells were serum starved for 16h and then treated with 250nM Torin 1 for 3h in 0.5% FBS.

RNA-Sequencing and Analysis

Total RNA was extracted from cells at day 7 ([Figure S1A](#)) with Trizol (Life Technologies) and DNase treated with RNeasy Mini Kit (QIAGEN, cat#74104) following the manufacturer's instructions. RNA integrity number (RIN) was measured using BioAnalyzer (Agilent Technologies) RNA 6000 Nano Kit to confirm RIN above 7 for each sample. The cDNA libraries were prepared using KAPA Stranded RNA-Seq Kits with RiboErase (Kapa Biosystems). Next generation sequencing was performed in The Penn State College of Medicine Genome Sciences and Bioinformatics Core facility as previously described in [Lynch et al. \(2015\)](#) using a HiSeq 2500 sequencer (Illumina). Demultiplexed and quality-filtered mRNA-Seq reads were then aligned to human reference genome (GRCh38) using TopHat (v.2.0.9). Differential expression analysis was done using Cuffdiff tool which is available by Cufflinks (v.2.0.2) as described in [Lynch et al. \(2015\)](#). Three technical replicates were used. Raw counts and differential expression analysis generated during this study are available at GEO (GSE133660).

Reverse Phase Protein Array (RPPA)

After 7 days under selection ([Figure S1A](#)), cells cultured in 10cm dishes were incubated on ice with 300 μL of lysis buffer (1% Triton X-100, 50mM HEPES pH = 7.5, 150mM NaCl, 1.5mM MgCl₂, 1mM EGTA, 100mM NaF, 10mM Na pyrophosphate, 1mM Na₃VO₄ and 10% glycerol) for 20 min with occasional shaking every 5 min. After incubation, cells were scraped off the plate and centrifuged at 18000 g for 10 min at 4°C. Total protein was quantified with Bradford assay and 90 μg of protein was diluted 3:1 in SDS sample buffer (40% glycerol, 8% SDS, 0.25M Tris-HCl and 10% B-mercaptoethanol). Lysates were boiled at 95°C for 5 min and stored at –80°C. RPPA data was generated and analyzed by the CCSG-supported RPPA Core Facility at the University of Texas MD Anderson Cancer Center ([Akbari et al., 2014](#)). A total of 240 authenticated Antibodies for total protein expression and 64 antibodies for protein phosphorylation were analyzed in this study. The complete antibody list can be found in <https://www.mdanderson.org/research/research-resources/core-facilities/functional-proteomics-rppa-core.html>.

Gene set enrichment analysis (GSEA)

Expression values included in the Talantov dataset (18 nevi and 45 primary melanoma tumors) ([Talantov et al., 2005](#)) were downloaded from GEO (GSE3189), while the expression values included in the Kabbarah dataset (9 nevi and 31 primary melanoma tumors) ([Kabbarah et al., 2010](#)) were downloaded from GEO (GSE46517). Gene Cluster Text files (GTC), as well as Categorical Class files (CLS) were generated independently for, RPPA, Talantov and Kabbarah datasets following the Gene Set Enrichment Analysis (GSEA) documentation indications (<http://software.broadinstitute.org/gsea/index.jsp>). GTC and CLS files were used to run independent GSEA analysis (javaGSEA desktop application). GSEA for Hallmarks, KEGG and Reactome were run independently under the following parameters: 1000 permutations, weighted enrichment analysis, signal to noise metric for ranking genes, and “meandiv” normalization mode. Following GSEA documentation indications, terms with p value < 0.05 and a q-value < 0.25 were considered significant ([Data S1](#)). For both, the RNA-Seq performed in this work (GSE133660) and Chicas dataset ([Chicas et al., 2010](#)) (GSE133660), genes were ranked according to the fold-change and p value obtained on the differential gene expression analysis as follows: $-\log_{10}(\text{p value}) \times \text{sign}(\log_2 \text{ fold change})$. Pre-ranked files were built up for the RNA-Seq and Chicas datasets and used to run pre-ranked GSEA ([Subramanian et al., 2005](#)) under predefined parameters following GSEA documentation indications.

Polysome fractionation

Eight culture plates per condition (~23 million cells per condition) were incubated with harringtonine (2 $\mu\text{g}/\text{mL}$) for 2 min at 37°C followed by 5 min of cycloheximide (100 $\mu\text{g}/\text{mL}$) treatment at 37°C. Cells were washed twice with PBS after each treatment. Cells were scraped in 600 μL of lysis buffer (50mM HEPES, 75mM KCl, 5mM MgCl₂, 250mM sucrose, 0.1mg/mL cycloheximide, 2mM DTT, 1% Triton X-100, 1.3% sodium deoxycholate and 5 μL of RNase OUT) on ice. Lysates were rocked for 10 min at 4°C and centrifuged at 3000 g for 15 min at 4°C. 400 μL of lysates supernatant (cytosolic cell extracts) were layered over cold sucrose gradients (10mM HEPES, 75mM KCl, 5mM MgCl₂, 0.5mM EDTA and increasing sucrose concentrations from 20% to 47%). Gradients were centrifuged at 34,000 rpms in a Beckman SW41 rotor for 2h and 40 min at 4°C. After centrifugation, light (0 to 2 ribosomes) and heavy

(< 2 ribosomes) polysome fractions were collected in Trizol (1:1) using a density gradient fractionation system (Brandel) equipped with a UA-6 absorbance detector and a R1 fraction collector.

RT-qPCR

Total RNA was extracted from cells with Trizol, DNase treated, cleaned, and concentrated using Zymo columns (Zymo Research, Cat# R1013) following the manufacturer's instructions. Similarly, mRNA from polysome fractions was DNase treated, cleaned, and concentrated using Zymo columns. Total RNA from tumor samples was isolated with NucleoSpin RNA/Protein following manufacturer's instructions. Optical density values of RNA were measured using NanoDrop One (Thermo Scientific) to confirm an A260 and A280 ratio above 1.9. Relative expression of target genes (listed in Table S2) were analyzed using the QuantStudio 3 Real-Time PCR System (Thermo Fisher Scientific) with clear 96 well plates (Greiner Bio-One). Primers were designed using the Integrated DNA Technologies (IDT) tool (<https://eu.idtdna.com/scitools/Applications/RealTimePCR/>) (Table S2). A total of 25ng of RNA was used for One-Step qPCR (Quanta BioSciences) following the manufacturer's instructions in a final volume of 10ul. Conditions for amplification were: 10 min at 48°C, 5 min at 95°C, 40 cycles of 10 s at 95°C and 7 s at the corresponding annealing temperature (Table S2). The assay ended with a melting curve program: 15 s at 95°C, 1 min at 70°C, then ramping to 95°C while continuously monitoring fluorescence. Alternatively, relative expression of *CDKN2A* was determined by adapting the method of Zhang et al. (2015). A total of 100ng of RNA was used for One-Step qPCR (Quanta BioSciences) following the manufacturer's instructions in a final volume of 10uL. Conditions for amplification were: 10 min at 48°C, 5 min at 95°C, 4 cycles of 10 s at 95°C and 10 s starting at 66°C and decreasing 2°C per cycle, 50 cycles of 10 s at 95°C and 7 s at 64°C. The assay ended with a melting curve program as above. Each sample was assessed in triplicate. Relative quantification was determined to multiple reference genes (*B2M*, *MRPL9*, *PSMC4*, and *PUM1*) using the delta-delta Ct method. The percentage of target gene mRNA in each polysome fraction was calculated as in Panda et al. (2017), but Ct values were first normalized to reference genes.

[35S]-methionine/cysteine incorporation followed by IP

After 16h of FBS starvation, cells were treated with 250nM Torin 1 or DMSO in media supplemented with 0.5% FBS for 3h. Thirty minutes prior to the end of Torin 1 treatment, 110uCi [35S]-methionine/cysteine was added to each plate. Cells were wash twice with PBS and pelleted. The pellet was resuspended in 100uL of denaturing Lysis buffer (1mM SDS and 5mM EDTA pH = 8) and boiled at 95°C for 5 min. Lysates were resuspended in 900uL of non-denaturing buffer (20mM Tris-HCl pH = 8, 137mM NaCl, 1mM EDTA pH = 8 and 1% Triton-X), sonicated, and centrifuged (10 min, 13,000 g, 4°C). The supernatant was collected, and the protein concentration was determined using the Bradford assay. 500ug of protein per condition was precleared with 15uL of magnetic beads (rotating 1h, 4°C). 5uL per sample of anti-RPIA or anti-IgG were bound to magnetic beads (rotating 3h, 4°C). Precleared samples were incubated with corresponding magnetic beads with conjugated antibodies (rotating overnight, 4°C). Magnetic beads were washed 3 times for 15 min each at 4°C with cold wash buffer (10mM Tris-HCl pH = 7.4, 1mM EDTA pH = 8, 1mM EGTA pH = 8, 150mM NaCl, 1% Triton-X, 0.2mM Na₃VO₄, 1mM PMSF and cOmplete Mini EDTA-free 1X). Immunoprecipitates were eluted in 10uL of 1X sample buffer (2% SDS, 10% glycerol, 0.01% bromophenol blue, 62.5mM Tris, pH 6.8, and 0.1M DTT) and boiled 10 min at 65°C and 1000rpm. Immunoprecipitates and 10% of input were separated under a 12% acrylamide gel. Acrylamide gel was stained with Coomassie blue and immunoprecipitated bands corresponding to RPIA (35kDa) were excised from the gel. Excised bands were weighted for normalization purposes before digestion with 1mL of electrode buffer (96mM Tris, 500mM glycine and 0.4% w/s SDS) for 16h at 4°C. Excised band suspensions were used to quantify the counts per minute (CPM) in a Beckman LS6500 scintillation counter. CPMs were normalized to corresponding band weights (mg).

Senescence and proliferation assays

SA-β-Gal staining was performed as previously described (Dimri et al., 1995). Cells were fixed in 2% formaldehyde/0.2% glutaraldehyde in PBS (5 min) and stained (40 mM Na₂HPO₄, 150 mM NaCl, 2 mM MgCl₂, 5 mM K₃Fe(CN)₆, 5 mM K₄Fe(CN)₆, and 1 mg/ml X-gal) overnight at 37°C in a non-CO₂ incubator. Images were acquired at room temperature using an inverted microscope (Nikon Eclipse Ts2) with a 20X/0.40 objective (Nikon LWD) equipped with a camera (Nikon DS-Fi3). Each sample was assessed in triplicate and at least 100 cells per well were counted (> 300 cells per experiment).

For BrdU incorporation, cells on coverslips were incubated with 1uM BrdU for 30 min (IMR90, ES2, and SKMe128) or 15 min (SW620, SW480, HT-29, PATU8902, and TCCSUP). Cells were fixed in 4% paraformaldehyde (10min), permeabilized in 0.2% Triton X-100 (5 min), and postfixed in 1% PF 0.01% Tween-20 (30 min). Cells were DNaseI treated (10 min) previous to blocking with 3% BSA/PBS (5 mins). Cells were incubated in anti-BrdU primary antibody in 3% BSA/PBS (1:500) for 1h followed by 3 washes using 1% Triton X-100. Cell were then incubated 1h in FITC anti-Rat secondary antibody in 3% BSA/PBS (1:1000). Finally, cells were incubated with 0.15 μg/ml DAPI in PBS (1 min), mounted, and sealed. Images were acquired at room temperature using a Nikon Eclipse 90i microscope with a 20x/0.17 objective (Nikon DIC N2 Plan Apo) equipped with a CoolSNAP Photometrics camera. Each sample was assessed in triplicate and at least 200 cells per well were counted (> 600 cells per experiment).

For colony formation, an equal number of cells were seeded in 6-well plates and cultured for an additional 2 weeks. Colony formation was visualized by fixing cells in 1% paraformaldehyde (5 min) and staining with 0.05% crystal violet (20 min). Wells were destained in 500 μL 10% acetic acid (5 min). Absorbance (590nm) was measured using a spectrophotometer (Spectra Max 190). Each sample was assessed in triplicate.

Temsirolimus half maximal inhibitory concentration (IC₅₀) assay

Twenty thousand cells per condition were plated in 12-well plates in triplicates. After 24 h regular media was replaced by 0.5% FBS supplemented media with increasing concentrations of temsirolimus (0uM, 0.07uM, 0.21uM, 0.62uM, 1.85uM, 5.56uM, 16.67uM and 50uM). After 5 days cells were fixed in 1% paraformaldehyde (5 min) and stained with 0.05% crystal violet (20 min). Wells were de-stained in 500uL 10% acetic acid (5 min). Absorbance (590nm) was measured using a spectrophotometer (Spectra Max 190). The half maximal inhibitory concentration (IC₅₀) was defined as the concentration resulting in a 50% reduction in absorbance.

Immunofluorescence

Cells were fixed in 4% paraformaldehyde (10min) and permeabilized in 0.2% Triton X-100 (5 min). Cells were blocked with 3% BSA/PBS (1h) and incubated in anti-mTORC (1/200) and anti-LAMP2 (1/100) in 3% BSA/PBS (16h) followed by 3 washes using 1% Triton X-100. Cells were then incubated in FITC anti-Rabbit (1/2000) and Cy3 anti-mouse (1/5000) secondary antibodies in 3% BSA/PBS (1 h). Finally, cells were incubated with 0.15 μ g/ml DAPI in PBS (1 min), mounted and sealed. Images were acquired at room temperature using a confocal microscope (Leica SP8) with a 64X oil objective. Co-localization analysis was performed using the Leica software in a total of 14 cells per sample.

Western blotting

Cell lysates were collected in 1X sample buffer (2% SDS, 10% glycerol, 0.01% bromophenol blue, 62.5mM Tris, pH 6.8, 0.1M DTT) and boiled (10 min at 95°C). Protein concentration was determined using the Bradford assay. Proteins were resolved using SDS-PAGE gels and transferred to nitrocellulose membranes (Fisher Scientific) (110mA for 2 h at 4°C). Membranes were blocked with 4% BSA in TBS containing 0.1% Tween-20 (TBS-T) for 1 h at room temperature. Membranes were incubated overnight at 4°C in primary antibodies in 4% BSA/TBS 0.025% sodium azide. Membranes were washed 4 times in TBS-T for 5 min at room temperature after which they were incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. After washing 4 times in TBS-T for 5 min at room temperature, proteins were visualized on film after incubation with SuperSignal West Pico PLUS Chemiluminescent Substrate (ThermoFisher, Waltham, MA).

Nucleotide Analysis by LC-HRMS

LC-HRMS for nucleotides and other polar metabolites was as previously described (Guo et al., 2016; Kuskovsky et al., 2019). Briefly, an Ultimate 3000 UHPLC equipped with a refrigerated autosampler (at 6°C) and a column heater (at 55°C) with a HSS C18 column (2.1 \times 100 mm i.d., 3.5 μ m; Waters) was used for separations. Solvent A was 5 mM DIPEA and 200 mM HFIP and solvent B was methanol with 5 mM DIPEA 200 mM HFIP. The gradient was as follows: 100% A for 3 min at 0.18 mL/min, 100% A at 6 min with 0.2 mL/min, 98% A at 8 min with 0.2 mL/min, 86% A at 12 min with 0.2 mL/min, 40% A at 16 min and 1% A at 17.9 min-18.5 min with 0.3 mL/min then increased to 0.4 mL/min until 20 min. Flow was ramped down to 0.18 mL/min back to 100% A over a 5 min re-equilibration. For MS analysis, the UHPLC was coupled to a Q Exactive HF mass spectrometer (Thermo Scientific) equipped with a HESI II source operating in negative mode. The operating conditions were as follows: spray voltage 4000 V; vaporizer temperature 200°C; capillary temperature 350°C; S-lens 60; in-source CID 1.0 eV, resolution 60,000. The sheath gas (nitrogen) and auxiliary gas (nitrogen) pressures were 45 and 10 (arbitrary units), respectively. Single ion monitoring (SIM) windows were acquired around the [M-H]⁻ of each analyte with a 20 *m/z* isolation window, 4 *m/z* isolation window offset, 1e⁶ ACG target and 80 ms IT, alternating in a Full MS scan from 70-950 *m/z* with 1e6 ACG, and 100 ms IT. Data was analyzed in XCalibur v4.0 and/or Tracefinder v4.1 (Thermo Scientific) using a 5 ppm window for integration of the peak area of all analytes. Used standards for nucleotides and deoxynucleotides both isotope labeled and non-labeled are indicated on the table. No suitable source of stable isotope labeled ADP, dADP, dTDP, CDP, or dCDP was found, thus the mono-phosphate was used as a surrogate internal standard. Guanine nucleotides were not quantified due to spectral overlap with the highly abundant adenine nucleotides.

Glucose labeling and analysis

Cells were seeded in 10 cm culture plates and at the end of the indicated treatment (Figure S1A) cells were washed twice with PBS and incubated 8h in DMEM (Cat# D5030) supplemented with 5mM of ¹³C₆-D-glucose, 0.5% of charcoal stripped FBS and 20mM of HEPES. Isotopologue patterns for dNDPs, dNTPs, and ribose-5-phosphate were analyzed by LC-HRMS as indicated above. Adjustment for natural isotopic abundance was conducted through open source and publicly available FluxFix (Trefely et al., 2016).

Flow Cytometry

For 7AAD staining both cells and media were collected and centrifuged (1000 rpm for 5 min) followed by resuspension in 500uL of 7AAD staining solution (5uL of 7AAD solution and 38mM NaCitrate). Stained cells were run on a 10-color FACSCanto flow cytometer (BD biosciences). Data were analyzed with FlowJo Software. Each sample was assessed in triplicate.

Murine tumor model

HT-29 colorectal carcinoma cells were infected with shRNA targeting p16 and RPIA alone or in combination. After 2 days of puromycin selection (3 μ g/mL), 3 million cells were resuspended in 200 μ L of PBS and injected subcutaneously into the left flank of SCID mice. Mice were monitored daily to identify palpable tumors. Mice weight and tumor length (L) and width (W) (L > W) were

measured every 3 days after a tumor volume of 200mm³. Tumor volume was calculated as 1/2 (L x W²). All animals were sacrificed at day 26 post injection and tumor tissues collected for following experiments. A total of 22 animals were used in this study (6 control, 6 shRPIA, 4 shp16 and 6 shp16/shRPIA).

QUANTIFICATION AND STATISTICAL ANALYSIS

GraphPad Prism version 7.0 was used to perform statistical analysis. The level of significance between two groups was assessed with unpaired t test. For dataset with more than two groups, one-way ANOVA followed by Tukey's post hoc test was applied. P values < 0.05 were considered significant. The IC₅₀ dose-response curves were plotted, and IC₅₀ values calculated using the log(inhibitor) versus normalized response function in GraphPad Prism Version 7.0. Kaplan-Meier survival plots differences between the two groups were analyzed with log-rank (Mantel-Cox) test using GraphPad Prism version 7.0. Data for the indicated tumors was obtained from cBioportal (Cerami et al., 2012; Gao et al., 2013). Unpaired t test between shRRM2/shp16 and shRRM2 alone was assessed with GraphPad Prism version 7.0 for each transcript included in the polysome fractionation experiment (Figure 3A; Table S1). P values were adjusted according to Benjamini and Hochberg's false discovery rate (FDR) and the percentage of shift between the light and the heavy fraction in shRRM2/shp16 was calculated (% transcript in heavy fraction - % transcript in light fraction) for each transcript. Hits were defined as those transcripts that were significantly (FDR P-value < 0.05) decreased in the light fraction and significantly (FDR P-value < 0.05) increased in the heavy fraction in shRRM2/shp16 when compared with shRRM2 alone. With these criteria we narrowed the list to three transcripts: ribose-5-phosphate isomerase A (*RPIA*), nucleoside diphosphate kinase A (*NME1*), and nucleoside diphosphate kinase 3 (*NME3*). *NME1/NME3* are known metastasis suppressors (Boissan et al., 2018); therefore, we focused on *RPIA*. Longitudinal and cross-sectional analysis of tumor volume were calculated using TumorGrowth tool with default parameters (Enot et al., 2018).

DATA AND CODE AVAILABILITY

The RNA-Seq generated during this study is available at GEO (<https://www.ncbi.nlm.nih.gov/geo/>) with accession number GSE133660.